IJCS | Volume 33, Nº1, January / February 2019

13 1. Lin CJ, Chua S, Chung SY, Hang CL, Tsai TH. Diabetes mellitus: an independent risk factor of in-hospital mortality in patients with infective endocarditis in a new era of clinical practice. Int J Environ Res Public Health. 2019;16(12):2248-58. 2. Bezerra RL, Carvalho TF, Batista RS, Silva YM, Campos BF, Castro JHM, et al. Association between insulin use and infective endocarditis: an observational study. Int J Cardiovasc Sci. 2020;33(1):14-21. 3. Olmos C, Vilacosta I, Pozo E, Fernández C, Sarriá C, López J, et al. Prognostic implications of diabetes in patients with left-sided endocarditis: findings from a large cohort study. Medicine (Baltimore). 2014;93(2):114-9. 4. Duval X, Alla F, Doco-Lecompte T, Lemoing V, Delahaye F, Mainardi JL, et al. Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality. Eur Heart J. 2007;28(1):59-64. References Cruz Filho Diabetes, insulin and infective endocarditis Int J Cardiovasc Sci. 2020;33(1):12-13 Editorial Given the increase of the diabetic population, mainly type 2 diabetic patients, and advances in the knowledge of pathophysiological mechanisms and therapeutic options, which has led to an increase in the life expectancy of these patients, improving the knowing of the development of IE in DM is justified. It is important to elucidate the possible increased risk of patients on insulin or other subcutaneous medication to have IE compared with non-diabetics or diabetic patients on oral medications. Also, the reports showing that S. aureus is the main pathogen responsible for IE, in addition to the increasing number of diabetic patients, call for the need to develop prophylactic measures against this pathogen. This is an open-access article distributed under the terms of the Creative Commons Attribution License